The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Anti-VEGF Therapeutic Market Research Report 2025
Synopsis
Anti–vascular endothelial growth factor therapy, also known as anti-VEGF therapy or medication, is the use of medications that block vascular endothelial growth factor.
Highlights
The global Anti-VEGF Therapeutic market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
North American market for Anti-VEGF Therapeutic is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
Asia-Pacific market for Anti-VEGF Therapeutic is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The major global manufacturers of Anti-VEGF Therapeutic include Regeneron Pharmaceuticals, Bayer, Novartis, Roche, Biogen, Pfizer, Coherus BioSciences, Amgen and Bausch Health Companies, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
The global market for Anti-VEGF Therapeutic in Macular Edema is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Aflibercept (Eylea), which accounted for % of the global market of Anti-VEGF Therapeutic in 2021, is expected to reach million US$ by 2028, growing at a revised CAGR of % from 2022 to 2028.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Anti-VEGF Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-VEGF Therapeutic.
The Anti-VEGF Therapeutic market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Anti-VEGF Therapeutic market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-VEGF Therapeutic manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Regeneron Pharmaceuticals
Bayer
Novartis
Roche
Biogen
Pfizer
Coherus BioSciences
Amgen
Bausch Health Companies
Viatris
Product Type Insights
Global markets are presented by Anti-VEGF Therapeutic type, along with growth forecasts through 2028. Estimates on sales and revenue are based on the price in the supply chain at which the Anti-VEGF Therapeutic are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).
Anti-VEGF Therapeutic segment by Type
Aflibercept (Eylea)
Ranibizumab (Lucentis)
Brolucizumab (Beovu)
Others
Application Insights
This report has provided the market size (sales and revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Anti-VEGF Therapeutic market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Anti-VEGF Therapeutic market.
Anti-VEGF Therapeutic segment by Application
Macular Edema
Diabetic Retinopathy
Retinal Vein Occlusion
Age-related Macular Degeneration
Others
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Anti-VEGF Therapeutic market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-VEGF Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Anti-VEGF Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Anti-VEGF Therapeutic industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-VEGF Therapeutic.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anti-VEGF Therapeutic manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anti-VEGF Therapeutic in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Analysis of sales channel, distributors and customers
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: sales and revenue forecast, global and regional, by Type and by Application. It provides a quantitative analysis of the market size and development potential of each market segment in the next six years.
Chapter 11: The main points and conclusions of the report.
Anti–vascular endothelial growth factor therapy, also known as anti-VEGF therapy or medication, is the use of medications that block vascular endothelial growth factor.
Highlights
The global Anti-VEGF Therapeutic market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
North American market for Anti-VEGF Therapeutic is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
Asia-Pacific market for Anti-VEGF Therapeutic is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The major global manufacturers of Anti-VEGF Therapeutic include Regeneron Pharmaceuticals, Bayer, Novartis, Roche, Biogen, Pfizer, Coherus BioSciences, Amgen and Bausch Health Companies, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
The global market for Anti-VEGF Therapeutic in Macular Edema is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Aflibercept (Eylea), which accounted for % of the global market of Anti-VEGF Therapeutic in 2021, is expected to reach million US$ by 2028, growing at a revised CAGR of % from 2022 to 2028.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Anti-VEGF Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-VEGF Therapeutic.
The Anti-VEGF Therapeutic market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Anti-VEGF Therapeutic market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-VEGF Therapeutic manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Regeneron Pharmaceuticals
Bayer
Novartis
Roche
Biogen
Pfizer
Coherus BioSciences
Amgen
Bausch Health Companies
Viatris
Product Type Insights
Global markets are presented by Anti-VEGF Therapeutic type, along with growth forecasts through 2028. Estimates on sales and revenue are based on the price in the supply chain at which the Anti-VEGF Therapeutic are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).
Anti-VEGF Therapeutic segment by Type
Aflibercept (Eylea)
Ranibizumab (Lucentis)
Brolucizumab (Beovu)
Others
Application Insights
This report has provided the market size (sales and revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Anti-VEGF Therapeutic market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Anti-VEGF Therapeutic market.
Anti-VEGF Therapeutic segment by Application
Macular Edema
Diabetic Retinopathy
Retinal Vein Occlusion
Age-related Macular Degeneration
Others
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Anti-VEGF Therapeutic market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-VEGF Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Anti-VEGF Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Anti-VEGF Therapeutic industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-VEGF Therapeutic.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anti-VEGF Therapeutic manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anti-VEGF Therapeutic in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Analysis of sales channel, distributors and customers
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: sales and revenue forecast, global and regional, by Type and by Application. It provides a quantitative analysis of the market size and development potential of each market segment in the next six years.
Chapter 11: The main points and conclusions of the report.
Index1 Anti-VEGF Therapeutic Market Overview
1.1 Product Overview and Scope of Anti-VEGF Therapeutic
1.2 Anti-VEGF Therapeutic Segment by Type
1.2.1 Global Anti-VEGF Therapeutic Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Aflibercept (Eylea)
1.2.3 Ranibizumab (Lucentis)
1.2.4 Brolucizumab (Beovu)
1.2.5 Others
1.3 Anti-VEGF Therapeutic Segment by Application
1.3.1 Global Anti-VEGF Therapeutic Sales Comparison by Application: (2022-2028)
1.3.2 Macular Edema
1.3.3 Diabetic Retinopathy
1.3.4 Retinal Vein Occlusion
1.3.5 Age-related Macular Degeneration
1.3.6 Others
1.4 Global Anti-VEGF Therapeutic Market Size Estimates and Forecasts
1.4.1 Global Anti-VEGF Therapeutic Revenue 2017-2028
1.4.2 Global Anti-VEGF Therapeutic Sales 2017-2028
1.4.3 Anti-VEGF Therapeutic Market Size by Region: 2017 Versus 2021 Versus 2028
2 Anti-VEGF Therapeutic Market Competition by Manufacturers
2.1 Global Anti-VEGF Therapeutic Sales Market Share by Manufacturers (2017-2022)
2.2 Global Anti-VEGF Therapeutic Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Anti-VEGF Therapeutic Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Anti-VEGF Therapeutic Manufacturing Sites, Area Served, Product Type
2.5 Anti-VEGF Therapeutic Market Competitive Situation and Trends
2.5.1 Anti-VEGF Therapeutic Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Anti-VEGF Therapeutic Players Market Share by Revenue
2.5.3 Global Anti-VEGF Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-VEGF Therapeutic Retrospective Market Scenario by Region
3.1 Global Anti-VEGF Therapeutic Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Anti-VEGF Therapeutic Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Anti-VEGF Therapeutic Market Facts & Figures by Country
3.3.1 North America Anti-VEGF Therapeutic Sales by Country
3.3.2 North America Anti-VEGF Therapeutic Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Anti-VEGF Therapeutic Market Facts & Figures by Country
3.4.1 Europe Anti-VEGF Therapeutic Sales by Country
3.4.2 Europe Anti-VEGF Therapeutic Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Anti-VEGF Therapeutic Market Facts & Figures by Region
3.5.1 Asia Pacific Anti-VEGF Therapeutic Sales by Region
3.5.2 Asia Pacific Anti-VEGF Therapeutic Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Anti-VEGF Therapeutic Market Facts & Figures by Country
3.6.1 Latin America Anti-VEGF Therapeutic Sales by Country
3.6.2 Latin America Anti-VEGF Therapeutic Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Anti-VEGF Therapeutic Market Facts & Figures by Country
3.7.1 Middle East and Africa Anti-VEGF Therapeutic Sales by Country
3.7.2 Middle East and Africa Anti-VEGF Therapeutic Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Anti-VEGF Therapeutic Historic Market Analysis by Type
4.1 Global Anti-VEGF Therapeutic Sales Market Share by Type (2017-2022)
4.2 Global Anti-VEGF Therapeutic Revenue Market Share by Type (2017-2022)
4.3 Global Anti-VEGF Therapeutic Price by Type (2017-2022)
5 Global Anti-VEGF Therapeutic Historic Market Analysis by Application
5.1 Global Anti-VEGF Therapeutic Sales Market Share by Application (2017-2022)
5.2 Global Anti-VEGF Therapeutic Revenue Market Share by Application (2017-2022)
5.3 Global Anti-VEGF Therapeutic Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Regeneron Pharmaceuticals
6.1.1 Regeneron Pharmaceuticals Corporation Information
6.1.2 Regeneron Pharmaceuticals Description and Business Overview
6.1.3 Regeneron Pharmaceuticals Anti-VEGF Therapeutic Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Regeneron Pharmaceuticals Anti-VEGF Therapeutic Product Portfolio
6.1.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Corporation Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Anti-VEGF Therapeutic Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Bayer Anti-VEGF Therapeutic Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Corporation Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis Anti-VEGF Therapeutic Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Novartis Anti-VEGF Therapeutic Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 Roche
6.4.1 Roche Corporation Information
6.4.2 Roche Description and Business Overview
6.4.3 Roche Anti-VEGF Therapeutic Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Roche Anti-VEGF Therapeutic Product Portfolio
6.4.5 Roche Recent Developments/Updates
6.5 Biogen
6.5.1 Biogen Corporation Information
6.5.2 Biogen Description and Business Overview
6.5.3 Biogen Anti-VEGF Therapeutic Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Biogen Anti-VEGF Therapeutic Product Portfolio
6.5.5 Biogen Recent Developments/Updates
6.6 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Anti-VEGF Therapeutic Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Pfizer Anti-VEGF Therapeutic Product Portfolio
6.6.5 Pfizer Recent Developments/Updates
6.7 Coherus BioSciences
6.6.1 Coherus BioSciences Corporation Information
6.6.2 Coherus BioSciences Description and Business Overview
6.6.3 Coherus BioSciences Anti-VEGF Therapeutic Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Coherus BioSciences Anti-VEGF Therapeutic Product Portfolio
6.7.5 Coherus BioSciences Recent Developments/Updates
6.8 Amgen
6.8.1 Amgen Corporation Information
6.8.2 Amgen Description and Business Overview
6.8.3 Amgen Anti-VEGF Therapeutic Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Amgen Anti-VEGF Therapeutic Product Portfolio
6.8.5 Amgen Recent Developments/Updates
6.9 Bausch Health Companies
6.9.1 Bausch Health Companies Corporation Information
6.9.2 Bausch Health Companies Description and Business Overview
6.9.3 Bausch Health Companies Anti-VEGF Therapeutic Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Bausch Health Companies Anti-VEGF Therapeutic Product Portfolio
6.9.5 Bausch Health Companies Recent Developments/Updates
6.10 Viatris
6.10.1 Viatris Corporation Information
6.10.2 Viatris Description and Business Overview
6.10.3 Viatris Anti-VEGF Therapeutic Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Viatris Anti-VEGF Therapeutic Product Portfolio
6.10.5 Viatris Recent Developments/Updates
7 Anti-VEGF Therapeutic Manufacturing Cost Analysis
7.1 Anti-VEGF Therapeutic Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Anti-VEGF Therapeutic
7.4 Anti-VEGF Therapeutic Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Anti-VEGF Therapeutic Distributors List
8.3 Anti-VEGF Therapeutic Customers
9 Anti-VEGF Therapeutic Market Dynamics
9.1 Anti-VEGF Therapeutic Industry Trends
9.2 Anti-VEGF Therapeutic Market Drivers
9.3 Anti-VEGF Therapeutic Market Challenges
9.4 Anti-VEGF Therapeutic Market Restraints
10 Global Market Forecast
10.1 Anti-VEGF Therapeutic Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Anti-VEGF Therapeutic by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Anti-VEGF Therapeutic by Type (2023-2028)
10.2 Anti-VEGF Therapeutic Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Anti-VEGF Therapeutic by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Anti-VEGF Therapeutic by Application (2023-2028)
10.3 Anti-VEGF Therapeutic Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Anti-VEGF Therapeutic by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Anti-VEGF Therapeutic by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of TablesList of Tables
Table 1. Global Anti-VEGF Therapeutic Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Anti-VEGF Therapeutic Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Anti-VEGF Therapeutic Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Anti-VEGF Therapeutic Market Competitive Situation by Manufacturers in 2021
Table 5. Global Anti-VEGF Therapeutic Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Anti-VEGF Therapeutic Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Anti-VEGF Therapeutic Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Anti-VEGF Therapeutic Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Anti-VEGF Therapeutic Average Price (US$/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Anti-VEGF Therapeutic Manufacturing Sites and Area Served
Table 11. Manufacturers Anti-VEGF Therapeutic Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Anti-VEGF Therapeutic by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-VEGF Therapeutic as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Anti-VEGF Therapeutic Sales by Region (2017-2022) & (K Units)
Table 16. Global Anti-VEGF Therapeutic Sales Market Share by Region (2017-2022)
Table 17. Global Anti-VEGF Therapeutic Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Anti-VEGF Therapeutic Revenue Market Share by Region (2017-2022)
Table 19. North America Anti-VEGF Therapeutic Sales by Country (2017-2022) & (K Units)
Table 20. North America Anti-VEGF Therapeutic Sales Market Share by Country (2017-2022)
Table 21. North America Anti-VEGF Therapeutic Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Anti-VEGF Therapeutic Revenue Market Share by Country (2017-2022)
Table 23. Europe Anti-VEGF Therapeutic Sales by Country (2017-2022) & (K Units)
Table 24. Europe Anti-VEGF Therapeutic Sales Market Share by Country (2017-2022)
Table 25. Europe Anti-VEGF Therapeutic Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Anti-VEGF Therapeutic Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Anti-VEGF Therapeutic Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Anti-VEGF Therapeutic Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Anti-VEGF Therapeutic Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Anti-VEGF Therapeutic Revenue Market Share by Region (2017-2022)
Table 31. Latin America Anti-VEGF Therapeutic Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Anti-VEGF Therapeutic Sales Market Share by Country (2017-2022)
Table 33. Latin America Anti-VEGF Therapeutic Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Anti-VEGF Therapeutic Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Anti-VEGF Therapeutic Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Anti-VEGF Therapeutic Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Anti-VEGF Therapeutic Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Anti-VEGF Therapeutic Revenue Market Share by Country (2017-2022)
Table 39. Global Anti-VEGF Therapeutic Sales by Type (2017-2022) & (K Units)
Table 40. Global Anti-VEGF Therapeutic Sales Market Share by Type (2017-2022)
Table 41. Global Anti-VEGF Therapeutic Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Anti-VEGF Therapeutic Revenue Share by Type (2017-2022)
Table 43. Global Anti-VEGF Therapeutic Price by Type (2017-2022) & (US$/Unit)
Table 44. Global Anti-VEGF Therapeutic Sales (K Units) by Application (2017-2022)
Table 45. Global Anti-VEGF Therapeutic Sales Market Share by Application (2017-2022)
Table 46. Global Anti-VEGF Therapeutic Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Anti-VEGF Therapeutic Revenue Share by Application (2017-2022)
Table 48. Global Anti-VEGF Therapeutic Price by Application (2017-2022) & (US$/Unit)
Table 49. Regeneron Pharmaceuticals Corporation Information
Table 50. Regeneron Pharmaceuticals Description and Business Overview
Table 51. Regeneron Pharmaceuticals Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 52. Regeneron Pharmaceuticals Anti-VEGF Therapeutic Product
Table 53. Regeneron Pharmaceuticals Recent Developments/Updates
Table 54. Bayer Corporation Information
Table 55. Bayer Description and Business Overview
Table 56. Bayer Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 57. Bayer Anti-VEGF Therapeutic Product
Table 58. Bayer Recent Developments/Updates
Table 59. Novartis Corporation Information
Table 60. Novartis Description and Business Overview
Table 61. Novartis Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 62. Novartis Anti-VEGF Therapeutic Product
Table 63. Novartis Recent Developments/Updates
Table 64. Roche Corporation Information
Table 65. Roche Description and Business Overview
Table 66. Roche Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 67. Roche Anti-VEGF Therapeutic Product
Table 68. Roche Recent Developments/Updates
Table 69. Biogen Corporation Information
Table 70. Biogen Description and Business Overview
Table 71. Biogen Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 72. Biogen Anti-VEGF Therapeutic Product
Table 73. Biogen Recent Developments/Updates
Table 74. Pfizer Corporation Information
Table 75. Pfizer Description and Business Overview
Table 76. Pfizer Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 77. Pfizer Anti-VEGF Therapeutic Product
Table 78. Pfizer Recent Developments/Updates
Table 79. Coherus BioSciences Corporation Information
Table 80. Coherus BioSciences Description and Business Overview
Table 81. Coherus BioSciences Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 82. Coherus BioSciences Anti-VEGF Therapeutic Product
Table 83. Coherus BioSciences Recent Developments/Updates
Table 84. Amgen Corporation Information
Table 85. Amgen Description and Business Overview
Table 86. Amgen Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 87. Amgen Anti-VEGF Therapeutic Product
Table 88. Amgen Recent Developments/Updates
Table 89. Bausch Health Companies Corporation Information
Table 90. Bausch Health Companies Description and Business Overview
Table 91. Bausch Health Companies Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 92. Bausch Health Companies Anti-VEGF Therapeutic Product
Table 93. Bausch Health Companies Recent Developments/Updates
Table 94. Viatris Corporation Information
Table 95. Viatris Description and Business Overview
Table 96. Viatris Anti-VEGF Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 97. Viatris Anti-VEGF Therapeutic Product
Table 98. Viatris Recent Developments/Updates
Table 99. Production Base and Market Concentration Rate of Raw Material
Table 100. Key Suppliers of Raw Materials
Table 101. Anti-VEGF Therapeutic Distributors List
Table 102. Anti-VEGF Therapeutic Customers List
Table 103. Anti-VEGF Therapeutic Market Trends
Table 104. Anti-VEGF Therapeutic Market Drivers
Table 105. Anti-VEGF Therapeutic Market Challenges
Table 106. Anti-VEGF Therapeutic Market Restraints
Table 107. Global Anti-VEGF Therapeutic Sales Forecast by Type (2023-2028) & (K Units)
Table 108. Global Anti-VEGF Therapeutic Sales Market Share Forecast by Type (2023-2028)
Table 109. Global Anti-VEGF Therapeutic Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 110. Global Anti-VEGF Therapeutic Revenue Market Share Forecast by Type (2023-2028)
Table 111. Global Anti-VEGF Therapeutic Sales Forecast by Application (2023-2028) & (K Units)
Table 112. Global Anti-VEGF Therapeutic Sales Market Share Forecast by Application (2023-2028)
Table 113. Global Anti-VEGF Therapeutic Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 114. Global Anti-VEGF Therapeutic Revenue Market Share Forecast by Application (2023-2028)
Table 115. Global Anti-VEGF Therapeutic Sales Forecast by Region (2023-2028) & (K Units)
Table 116. Global Anti-VEGF Therapeutic Sales Market Share Forecast by Region (2023-2028)
Table 117. Global Anti-VEGF Therapeutic Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 118. Global Anti-VEGF Therapeutic Revenue Market Share Forecast by Region (2023-2028)
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Anti-VEGF Therapeutic
Figure 2. Global Anti-VEGF Therapeutic Market Share by Type in 2021 & 2028
Figure 3. Aflibercept (Eylea) Product Picture
Figure 4. Ranibizumab (Lucentis) Product Picture
Figure 5. Brolucizumab (Beovu) Product Picture
Figure 6. Others Product Picture
Figure 7. Global Anti-VEGF Therapeutic Market Share by Application in 2021 & 2028
Figure 8. Macular Edema
Figure 9. Diabetic Retinopathy
Figure 10. Retinal Vein Occlusion
Figure 11. Age-related Macular Degeneration
Figure 12. Others
Figure 13. Global Anti-VEGF Therapeutic Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Anti-VEGF Therapeutic Market Size (2017-2028) & (US$ Million)
Figure 15. Global Anti-VEGF Therapeutic Sales (2017-2028) & (K Units)
Figure 16. Anti-VEGF Therapeutic Sales Share by Manufacturers in 2021
Figure 17. Global Anti-VEGF Therapeutic Revenue Share by Manufacturers in 2021
Figure 18. The Global 5 and 10 Largest Anti-VEGF Therapeutic Players: Market Share by Revenue in 2021
Figure 19. Anti-VEGF Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 20. Global Anti-VEGF Therapeutic Sales Market Share by Region (2017-2022)
Figure 21. Global Anti-VEGF Therapeutic Sales Market Share by Region in 2021
Figure 22. Global Anti-VEGF Therapeutic Revenue Market Share by Region (2017-2022)
Figure 23. Global Anti-VEGF Therapeutic Revenue Market Share by Region in 2021
Figure 24. United States Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. Canada Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. Germany Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. France Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. U.K. Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. Italy Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. Russia Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. China Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Japan Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. South Korea Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. India Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Australia Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. China Taiwan Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Indonesia Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Thailand Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Malaysia Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Mexico Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Brazil Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Argentina Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Turkey Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. Saudi Arabia Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 45. UAE Anti-VEGF Therapeutic Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 46. Sales Market Share of Anti-VEGF Therapeutic by Type (2017-2022)
Figure 47. Manufacturing Cost Structure of Anti-VEGF Therapeutic
Figure 48. Manufacturing Process Analysis of Anti-VEGF Therapeutic
Figure 49. Anti-VEGF Therapeutic Industrial Chain Analysis
Figure 50. Channels of Distribution
Figure 51. Distributors Profiles
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
